Hematological malignancies encompass a diverse range of diseases, such as leukemia, lymphoma, and multiple myeloma, among others. Within the multidisciplinary treatment approach, radiation therapy ...

Annual meeting moves to the New York Marriott Marquis on October 13-16, marking a new chapter and providing a refreshed ...

Hepta refractory multiple myeloma is marked by antigen loss, genomic complexity, and 12.8 month median survival in multi centre data.

Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...

Ameet Patel, MD, concludes by outlining strategies to overcome operational, financial, and payer challenges in delivering advanced multiple myeloma therapies.

In a Phase III randomized trial, Mass General Brigham researchers found that stereotactic radiation targeting individual tumors led to lower symptom burden, better cognitive outcomes, and better ...

Study expected to enroll 24 patients with the option to enroll an additional 45 patients at the recommended Phase 2 doseProtocol calls for three ...

Recent regulatory actions from the FDA, including new drug application (NDA) acceptances and labeling updates, introduce new clinical considerations for oncology nurses and advanced practice providers ...

A myeloma survivor in long remission shares how research, expert care and advocacy turned fear into hope as more patients ...

Bristol Myers Squibb BMY announced that the FDA has accepted the new drug application (NDA) for its pipeline candidate, iberdomide, in combination with standard therapies (daratumumab and ...

The NDA is supported by data from the EXCALIBER-RRMM trial, which evaluated the safety and efficacy of iberdomide, an investigational cereblon E3 ligase modulator.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2025 Earnings Call Transcript February 17, 2026 Halozyme Therapeutics, Inc.